Baidu
map

2019 JSS指南:静脉溶栓治疗(重组组织型纤溶酶原激活剂)-第3版

2019-12-05 日本卒中学会 Neurol Med Chir (Tokyo). 2019 Dec 5.

2019年3月,日本卒中学会(JSS)发布了静脉溶栓治疗指南第三版,指南主要内容涉及11部分内容,主要建议涉及治疗药物,静脉溶栓治疗时间窗,治疗条件,接受抗凝治疗患者的治疗资格,医疗机构必备要素,症状发作到入院的流程,用药史,医学检查和实验室检查,影像学诊断,患者知情同意,血管内治疗,静脉溶栓后管理。

中文标题:

2019 JSS指南:静脉溶栓治疗(重组组织型纤溶酶原激活剂)-第3版

英文标题:

Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society.

发布机构:

日本卒中学会

发布日期:

2019-12-05

简要介绍:

2019年3月,日本卒中学会(JSS)发布了静脉溶栓治疗指南第三版,指南主要内容涉及11部分内容,主要建议涉及治疗药物,静脉溶栓治疗时间窗,治疗条件,接受抗凝治疗患者的治疗资格,医疗机构必备要素,症状发作到入院的流程,用药史,医学检查和实验室检查,影像学诊断,患者知情同意,血管内治疗,静脉溶栓后管理。

 

拓展指南:溶栓相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 JSS指南:静脉溶栓治疗(重组组织型纤溶酶原激活剂)-第3版)] GetToolGuiderByIdResponse(projectId=1, id=0ddd61c001839520, title=2019 JSS指南:静脉溶栓治疗(重组组织型纤溶酶原激活剂)-第3版, enTitle=Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society., guiderFrom=Neurol Med Chir (Tokyo). 2019 Dec 5., authorId=null, author=, summary=2019年3月,日本卒中学会(JSS)发布了静脉溶栓治疗指南第三版,指南主要内容涉及11部分内容,主要建议涉及治疗药物,静脉溶栓治疗时间窗,治疗条件,接受抗凝治疗患者的治疗资格,医疗机构必备要素,症状发作到入院的流程,用药史,医学检查和实验室检查,影像学诊断,患者知情同意,血管内治疗,静脉溶栓后管理。 , cover=, journalId=null, articlesId=null, associationId=1857, associationName=日本卒中学会, associationIntro= ), copyright=0, guiderPublishedTime=Thu Dec 05 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>2019年3月,日本卒中学会(JSS)发布了静脉溶栓治疗指南第三版,指南主要内容涉及11部分内容,主要建议涉及治疗药物,静脉溶栓治疗时间窗,治疗条件,接受抗凝治疗患者的治疗资格,医疗机构必备要素,症状发作到入院的流程,用药史,医学检查和实验室检查,影像学诊断,患者知情同意,血管内治疗,静脉溶栓后管理。 </P> <P> </P>拓展指南:<STRONG>与<FONT color=red>溶栓</FONT>相关指南:</STRONG><BR> <UL> <LI><A title=广东省深静脉导管接触性溶栓护理实践专家共识 target=_blank href="//m.capotfarm.com/guideline/show_article.do?id=c8e051c001829874">广东省深静脉导管接触性溶栓护理实践专家共识</A> <LI><A title=急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版) target=_blank href="//m.capotfarm.com/guideline/show_article.do?id=295531c001e023b7">急性ST段抬高型心肌梗死溶栓治疗的合理用药指南(第2版)</A> <LI><A title=ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识 target=_blank href="//m.capotfarm.com/guideline/show_article.do?id=5cc351c00158a352">ST段抬高型急性心肌梗死院前溶栓治疗中国专家共识</A> <LI><A title="2018 ASRA循证指南:接受抗栓或溶栓治疗患者进行区域阻滞麻醉(第4版)" target=_blank href="//m.capotfarm.com/guideline/show_article.do?id=5a7681c0015e21f3">2018 ASRA循证指南:接受抗栓或溶栓治疗患者进行区域阻滞麻醉(第4版)</A> <LI><A title="2017 AHA/ASA科学声明:急性缺血性脑卒中静脉阿替普酶溶栓后出血性转化的治疗和结局" target=_blank href="//m.capotfarm.com/guideline/show_article.do?id=baaaf1c00151e87e">2017 AHA/ASA科学声明:急性缺血性脑卒中静脉阿替普酶溶栓后出血性转化的治疗和结局</A> 更多信息请点击:<A target=_blank href="//m.capotfarm.com/guideline/list.do?q=%E6%BA%B6%E6%A0%93">有关溶栓更多指南</A></LI></UL>, tagList=[TagDto(tagId=17528, tagName=静脉溶栓治疗), TagDto(tagId=97942, tagName=重组组织型纤溶酶原激活剂)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10398, appHits=593, showAppHits=3, pcHits=4645, showPcHits=6553, likes=99, shares=23, comments=13, approvalStatus=1, publishedTime=Mon Dec 16 23:04:49 CST 2019, publishedTimeString=2019-12-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Dec 16 23:04:49 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 22:11:12 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 JSS指南:静脉溶栓治疗(重组组织型纤溶酶原激活剂)-第3版)])
2019 JSS指南:静脉溶栓治疗(重组组织型纤溶酶原激活剂)-第3版
下载请点击:
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1079345, encodeId=0b6410e9345f1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471e6398584, createdName=ms9000000609457014, createdTime=Sun Dec 12 23:37:19 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075838, encodeId=9ba310e583807, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Wed Dec 01 12:33:38 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950895, encodeId=12fa95089576, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:11:46 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916012, encodeId=13cb91601268, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a75452251, createdName=ms6000000226490121, createdTime=Tue Jan 12 20:08:55 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914726, encodeId=a08a914e260a, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b685446796, createdName=画谁, createdTime=Fri Jan 08 20:44:46 CST 2021, time=2021-01-08, status=1, ipAttribution=)]
    2021-12-12 ms9000000609457014

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1079345, encodeId=0b6410e9345f1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471e6398584, createdName=ms9000000609457014, createdTime=Sun Dec 12 23:37:19 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075838, encodeId=9ba310e583807, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Wed Dec 01 12:33:38 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950895, encodeId=12fa95089576, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:11:46 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916012, encodeId=13cb91601268, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a75452251, createdName=ms6000000226490121, createdTime=Tue Jan 12 20:08:55 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914726, encodeId=a08a914e260a, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b685446796, createdName=画谁, createdTime=Fri Jan 08 20:44:46 CST 2021, time=2021-01-08, status=1, ipAttribution=)]
    2021-12-01 ms2000000371747721

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1079345, encodeId=0b6410e9345f1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471e6398584, createdName=ms9000000609457014, createdTime=Sun Dec 12 23:37:19 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075838, encodeId=9ba310e583807, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Wed Dec 01 12:33:38 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950895, encodeId=12fa95089576, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:11:46 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916012, encodeId=13cb91601268, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a75452251, createdName=ms6000000226490121, createdTime=Tue Jan 12 20:08:55 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914726, encodeId=a08a914e260a, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b685446796, createdName=画谁, createdTime=Fri Jan 08 20:44:46 CST 2021, time=2021-01-08, status=1, ipAttribution=)]
    2021-03-25 ms8000001914536834

    学习使人进步

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1079345, encodeId=0b6410e9345f1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471e6398584, createdName=ms9000000609457014, createdTime=Sun Dec 12 23:37:19 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075838, encodeId=9ba310e583807, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Wed Dec 01 12:33:38 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950895, encodeId=12fa95089576, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:11:46 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916012, encodeId=13cb91601268, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a75452251, createdName=ms6000000226490121, createdTime=Tue Jan 12 20:08:55 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914726, encodeId=a08a914e260a, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b685446796, createdName=画谁, createdTime=Fri Jan 08 20:44:46 CST 2021, time=2021-01-08, status=1, ipAttribution=)]
    2021-01-12 ms6000000226490121

    想学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1079345, encodeId=0b6410e9345f1, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471e6398584, createdName=ms9000000609457014, createdTime=Sun Dec 12 23:37:19 CST 2021, time=2021-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075838, encodeId=9ba310e583807, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fe55613728, createdName=ms2000000371747721, createdTime=Wed Dec 01 12:33:38 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950895, encodeId=12fa95089576, content=学习使人进步, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210706/fed1c69edef040aa845e61835a8d1382/53e965c9bdde4992a6e934a143e0aef7.jpg, createdBy=686b5468799, createdName=ms8000001914536834, createdTime=Thu Mar 25 01:11:46 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916012, encodeId=13cb91601268, content=想学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7a75452251, createdName=ms6000000226490121, createdTime=Tue Jan 12 20:08:55 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914726, encodeId=a08a914e260a, content=。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b685446796, createdName=画谁, createdTime=Fri Jan 08 20:44:46 CST 2021, time=2021-01-08, status=1, ipAttribution=)]
    2021-01-08 画谁

    0

Baidu
map
Baidu
map
Baidu
map